Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-551-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$99.24 million
Profitability
Miscellaneous
Employees398
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health Inc (NASDAQ:RDUS) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.86) by $0.09. The biopharmaceutical company earned $41.04 million during the quarter, compared to analysts' expectations of $40.60 million. Radius Health had a negative return on equity of 368.58% and a negative net margin of 127.22%. The firm's quarterly revenue was up 81.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.99) EPS. View Radius Health's Earnings History.
When is Radius Health's next earnings date?
What guidance has Radius Health issued on next quarter's earnings?
Radius Health issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $171.6 million.
What price target have analysts set for RDUS?
6 brokerages have issued 12 month price objectives for Radius Health's shares. Their forecasts range from $22.00 to $52.00. On average, they expect Radius Health's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 42.7% from the stock's current price. View Analyst Price Targets for Radius Health.
What is the consensus analysts' recommendation for Radius Health?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. HC Wainwright analysts commented, "Our $26 price target is based on an 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and $300M peak oral Korsuva sales in Stage 3-5 CKD (the latter even further risk-adjusted to <$100M in our model at 30% probability of success pre-Phase 2). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028. If our DCF valuation with IV Korsuva entirely de-risked (and oral still at 30%), all else equal, would yield a CKD-aP driven valuation of $35/share. That does not yet include any explicit value for Korsuva ex-U.S."" (5/9/2019)
- 2. According to Zacks Investment Research, "Radius’ lead drug, Tymlos, continues to gain traction. In the first six weeks of 2019, the drug captured a 29% share of the U.S. anabolic osteoporosis market and more than 40% of new anabolic patient starts. Tymlos captured, on average, 20% of the U.S. anabolic osteoporosis market in 2018. In the fourth quarter, the drug’s average U.S. anabolic market share grew to 26% and achieved a 39% share of new anabolic patient starts. However, Radius suffered a setback when the European Commission refused to approve the drug. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded with the presence of drugs like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the past twelve months." (5/6/2019)
Has Radius Health been receiving favorable news coverage?
Media headlines about RDUS stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Radius Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Radius Health.
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), United Therapeutics (UTHR), FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS) and Genmab A/S (GMAB).
What other stocks do shareholders of Radius Health own?
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
- Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
- Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Brian Nicholas Harvey, Advisor (Age 58)
- Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board
Who are Radius Health's major shareholders?
Radius Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.33%), Rhumbline Advisers (0.15%) and Foundry Partners LLC (0.07%). Company insiders that own Radius Health stock include Anthony Rosenberg, Brent Hatzis-Schoch, Debasish Roychowdhury, Growth N V Biotech, Jesper Hoiland, Jessica Hopfield, Joseph Francis Kelly and Willard H Dere. View Institutional Ownership Trends for Radius Health.
Which major investors are buying Radius Health stock?
RDUS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Foundry Partners LLC and Rhumbline Advisers. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland, Jessica Hopfield and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $27.33.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.26 billion and generates $99.24 million in revenue each year. The biopharmaceutical company earns $-221,340,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis. Radius Health employs 398 workers across the globe.View Additional Information About Radius Health.
What is Radius Health's official website?
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
